Clinical Trial Details

Inclusion criteria

• Male subjects aged >18 years.
• Patients with confirmed Gleason score of 8 - 10 prostate cancer, had at least one prostate mpMRI and one prostate biopsy.
• Ability to lie still for MRI scanning.
• Patients must be able to provide written informed consent.
• Glomerular filtration rate (GFR) > 60 mL/min within a 30 days of the research MRI.

Key exclusion criteria

• Any diagnosis of active acute, chronic, or sub-chronic kidney or liver disease.
• Documented acute prostatitis, symptomatic or severe benign prostatic hyperplasia (BPH) or urinary tract infections.
• Patients with uncontrolled diabetes or hypertension.
• Patients with active non-prostate malignancy.
• Patients with contraindications for MRI including implantable pace makers, cochlear implants.
• Patients with uni- or bilateral hip prosthesis.
• Subjects with other significant medical conditions that would create unacceptable operative risk, compromise retention on study or compromise study related assessments.
• Major surgery within 4 weeks prior to entry on this study or patients who have not recovered from side effects of such therapy.
• Prostate biopsy within 4 weeks prior to entry on this study in which inflammation might affect MRI result.
• Subjects who received or will receive any other MRI contrast agent within 48 hours prior to MT218 injection or up to 24 hours after MT218 injection.
• Is determined by the investigator that the patient is clinically unsuitable for the study.
• Is incapable of understanding the language in which the information for the patient is given.
• Participation in a concurrent clinical trial or in another trial within the past 30 days.